Therapeutic Goods Administration
Australia's medicines and devices regulator, a Project Orbis and Access Consortium partner that registers cancer drugs before PBAC decides whether to subsidise them.
Part of the Australian Government Department of Health, the TGA regulates medicines, devices, blood and tissues and maintains the Australian Register of Therapeutic Goods. It participates in the FDA's Project Orbis and in the Access Consortium with Canada, Singapore, Switzerland and the UK, sharing assessments so cancer drugs can be approved in Australia at close to the same time as in the US. Priority and provisional approval pathways allow earlier registration of promising drugs on preliminary data, and the TGA also regulates radiopharmaceuticals, which matters for Australia's leadership in PSMA theranostics. Subsidy is a separate decision by the Pharmaceutical Benefits Advisory Committee.
- Project Orbis and Access Consortium
- Priority and provisional approval pathways
- Radiopharmaceutical regulation
- Device and software-as-a-medical-device regulation
Pages like this
not linked directly; found by shared links- InstitutionEuropean Medicines Agency
Shares Swissmedic, Medicines and Healthcare products Regulatory Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- InstitutionCancer Council Australia
Shares Pharmaceutical Benefits Advisory Committee, ANZUP Cancer Trials Group.
- InstitutionComisión Federal para la Protección contra Riesgos Sanitarios
Shares FDA Oncology Center of Excellence, Regulatory divergence between regions.
- PersonShahneen Sandhu
Shares ANZUP Cancer Trials Group, Radioligand therapy (beta emitters).
- IdeaMutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants
Shares Regulatory divergence between regions, Radioligand therapy (beta emitters).
- InstitutionMovember
Shares ANZUP Cancer Trials Group, Radioligand therapy (beta emitters).
- TrialTheraP (ANZUP 1603)
Shares ANZUP Cancer Trials Group, Radioligand therapy (beta emitters).
- InstitutionPharmaceuticals and Medical Devices Agency
Shares FDA Oncology Center of Excellence, Regulatory divergence between regions.